Targeting MUC1-C to improve immunotherapy for lung cancer
MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer
['FUNDING_R21'] · DANA-FARBER CANCER INST · NIH-10865865
This study is looking at a way to make immunotherapy better for people with non-small cell lung cancer by targeting a specific protein that helps tumors hide from the immune system, especially in patients with certain gene mutations, to help improve their treatment results.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10865865 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing immunotherapy for non-small cell lung cancer (NSCLC) by targeting a protein called MUC1-C, which plays a role in immune evasion. The study investigates how MUC1-C contributes to the suppression of the immune response in tumors, particularly in cases where patients have mutations in the EGFR gene. By using genetically engineered mouse models, researchers aim to develop new antibody-drug conjugates that can effectively counteract this immune suppression and improve treatment outcomes for patients with NSCLC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, especially those with EGFR mutations.
Not a fit: Patients with other types of lung cancer or those who do not have EGFR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with non-small cell lung cancer, particularly those resistant to current treatments.
How similar studies have performed: Previous studies have shown promise in targeting similar pathways in cancer treatment, indicating that this approach could be effective.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KUFE, DONALD W. — DANA-FARBER CANCER INST
- Study coordinator: KUFE, DONALD W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Patient, Cancer Treatment, Cancer cell line, Cancers